IN8bio (NASDAQ:INAB) Posts Quarterly Earnings Results

IN8bio (NASDAQ:INAB) announced its earnings results on Thursday. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.08), FiscalAI reports.

IN8bio Trading Down 4.0%

INAB stock traded down $0.08 during trading on Thursday, hitting $1.91. 41,127 shares of the stock traded hands, compared to its average volume of 70,048. IN8bio has a one year low of $1.17 and a one year high of $7.58. The company has a 50 day simple moving average of $2.02 and a 200 day simple moving average of $1.99. The stock has a market cap of $18.66 million and a price-to-earnings ratio of -0.35.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Captrust Financial Advisors acquired a new position in IN8bio during the 4th quarter worth about $43,000. Alyeska Investment Group L.P. increased its position in IN8bio by 1,060.8% in the 4th quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock valued at $2,231,000 after acquiring an additional 875,000 shares in the last quarter. HRT Financial LP bought a new position in shares of IN8bio in the fourth quarter worth about $34,000. Franklin Resources Inc. lifted its position in shares of IN8bio by 381.6% during the fourth quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after purchasing an additional 724,637 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of IN8bio during the third quarter valued at approximately $54,000. 92.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on INAB shares. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a report on Thursday, January 22nd. Zacks Research upgraded shares of IN8bio to a “hold” rating in a research note on Thursday, January 15th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, IN8bio presently has an average rating of “Hold” and an average target price of $92.00.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.